Provided herein are compounds of Formula (I),

##STR00001##

a compound selected from any of the compounds in Table 1, Table 2, Table 3, or a pharmaceutically acceptable salt or deuterated form thereof, wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I), or a compound selected from any of the compounds in Table 1, Table 2, Table 3, or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in treating 5-HT.sub.2A receptor associated diseases or disorders.

An electrolyte for a lithium secondary battery according to exemplary embodiments of the present inventing includes an organic solvent, a lithium salt, a first additive represented by a predetermined chemical formula, and a second additive represented by a predetermined chemical formula. A protective film is formed by the additives to suppress an expansion of a lithium secondary battery and improve storage property at high temperature.

The invention provides a compound of formula (I) ##STR00001## wherein B is a nucleobase; U is O or S; R.sup.x is OC(O)R.sup.y, OC(O)CH(R.sup.y)NH.sub.2, OCH.sub.2OC(O)R.sup.y; R.sup.y is optionally substituted alkyl or alkenyl or the side chain of a natural or unnatural amino acid R.sup.1 is H, or optionally substituted phenyl, benzyl, naphthyl, pyridyl or indolyl, or R.sup.x and R.sup.1 together define a bond thus forming a cyclic phosphate; R.sup.2 and R.sup.2 together define the side chain of a natural or unnatural amino acid; R.sup.3 is optionally substituted alkyl, cycloalkyl, phenyl or benzyl; and pharmaceutically acceptable salts and compositions thereof which are useful in the treatment of cancer, especially leukemias.

Process with universal usefulness for reducing the chlorine content of organomonophosphites, using two solutions.

The invention relates to a universally applicable method for reducing the chlorine content of organomonophosphites using dimethylaminobutane or triethylamine.

Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomersynthesis while maintaining overall yield and purity of a synthesized oligomer.

New ampholyte biomaterial compounds containing ampholyte moieties are synthesized and integrated into polymeric assemblies to provide hydrophilic polymers exhibiting improved biocompatibility, haemocompatibility, hydrophilicity non-thrombogenicity, anti-bacterial ability, and mechanical strength, as well as suitability as a drug delivery platform.

Here provided are a salt of Z)O-octadec-9-en-1-yl O,O-dihydrogen phosphorothioate with an L-lysine addition in crystalline form and methods of making and using the same.

A stabilizer including a first component and a second component. The first component is a compound represented by the formula (1). ##STR00001## The second component is a compound represented by the formula (2). ##STR00002##

An electrolyte solution for a rechargeable lithium battery includes a non-aqueous organic solvent, a lithium salt; and an additive, wherein the additive includes a first compound and a second compound.